abivertinib
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 31, 2019 (NCT03856697)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
- Epidermal growth factor receptorINHIBITOR
Epidermal growth factor receptor inhibitor
Epidermal growth factor receptor erbB1 inhibitor
Enhanced activity against 'activated' and T790M-type EGFR mutants
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1- Mol. weight
- 487.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297865 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05361915 | Phase 2 | Oct 31, 2022 | Sorrento Therapeutics, Inc. |
| NCT04528667 | Phase 2 | Dec 31, 2020 | Sorrento Therapeutics, Inc. |
| NCT04440007 | Phase 2 | Aug 31, 2020 | Sorrento Therapeutics, Inc. |
| NCT03856697 | Phase 3 | Mar 31, 2019 | Acea Bio, Shantou University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sorrento Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2020 |
| Acea Bio | For profit | 1 | 1 | 1 | 2019 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1